Nothing Special   »   [go: up one dir, main page]

ES464193A1 - Procedimiento para la preparacion de espirolactonas. - Google Patents

Procedimiento para la preparacion de espirolactonas.

Info

Publication number
ES464193A1
ES464193A1 ES464193A ES464193A ES464193A1 ES 464193 A1 ES464193 A1 ES 464193A1 ES 464193 A ES464193 A ES 464193A ES 464193 A ES464193 A ES 464193A ES 464193 A1 ES464193 A1 ES 464193A1
Authority
ES
Spain
Prior art keywords
image
spirolactones
formula
new
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES464193A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5993550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES464193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of ES464193A1 publication Critical patent/ES464193A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Procedimiento para la preparación de espirolactonas de la fórmula general I*** (ver fórmulas)
ES464193A 1976-11-16 1977-11-16 Procedimiento para la preparacion de espirolactonas. Expired ES464193A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2652761A DE2652761C2 (de) 1976-11-16 1976-11-16 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
ES464193A1 true ES464193A1 (es) 1978-09-01

Family

ID=5993550

Family Applications (1)

Application Number Title Priority Date Filing Date
ES464193A Expired ES464193A1 (es) 1976-11-16 1977-11-16 Procedimiento para la preparacion de espirolactonas.

Country Status (23)

Country Link
US (1) US4129564A (es)
JP (2) JPS5363373A (es)
AT (1) AT356827B (es)
AU (1) AU512611B2 (es)
BE (1) BE860877A (es)
CA (1) CA1092094A (es)
CH (2) CH631463A5 (es)
CS (1) CS194823B2 (es)
DD (1) DD132968B3 (es)
DE (1) DE2652761C2 (es)
DK (1) DK141967C (es)
ES (1) ES464193A1 (es)
FR (1) FR2370755A1 (es)
GB (1) GB1550568A (es)
GR (1) GR65227B (es)
HU (1) HU174983B (es)
IE (1) IE46076B1 (es)
IL (1) IL53353A (es)
IT (1) IT1092262B (es)
LU (1) LU78514A1 (es)
NL (1) NL7711946A (es)
SE (1) SE436425B (es)
SU (2) SU695560A3 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3051166C2 (en) * 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel
EP0075189B1 (en) * 1981-09-21 1985-08-28 Schering Aktiengesellschaft 3-beta,7-beta,15-alpha-trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and its preparation
DE3213962A1 (de) * 1982-04-13 1983-10-13 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).2(alpha);6(beta).7(beta).15(beta).16(beta)-trimethylen-3-oxo-17(alpha)-pregn-4-en-21.17-carbolacton, dessen herstellung und verwendung als arzneimittel
DE3227598A1 (de) * 1982-07-22 1984-01-26 Schering AG, 1000 Berlin und 4709 Bergkamen 7(alpha)-acylthio-15.16-methylen-3-oxo-17(alpha)-pregna-1.4-dien-21,17-carbolactone, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3234972A1 (de) * 1982-09-17 1984-03-22 Schering AG, 1000 Berlin und 4709 Bergkamen 7(alpha)-alkyl-17(alpha)-pregn-4-en-21.17-carbolactone und -21-carbonsaeuresalze sowie verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3240510A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 7(alpha)-acylthio-1(alpha),2(alpha)-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, deren herstellung und diese enthaltende arzneimittel
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3306554A1 (de) * 1983-02-22 1984-08-23 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 3-((delta)(pfeil hoch)4(pfeil hoch)-3-ketosteroid-17(alpha)-yl)-propionsaeurelactonen
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3481707D1 (de) * 1983-08-17 1990-04-26 Schering Ag 7-alpha-substituierte 3-oxo-17alpha-pregn-4-en-21.17-carbolactone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3347510A1 (de) * 1983-12-27 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 3-oxo-17(alpha)-pregna-4,6-dien-21,17-carbolactonen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
JPS6248694A (ja) * 1985-08-28 1987-03-03 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3544661A1 (de) * 1985-12-13 1987-06-19 Schering Ag Verfahren zur herstellung von 7(alpha)-acetylthiosteroiden
JPS62132932U (es) * 1986-02-14 1987-08-21
US4837211A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
JPS6453026U (es) * 1987-09-29 1989-03-31
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
ES2175098T3 (es) * 1995-06-07 2002-11-16 Searle & Co Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
AU1714000A (en) * 1998-11-06 2000-05-29 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
RU2269342C2 (ru) * 1999-08-31 2006-02-10 Шеринг Акциенгезелльшафт Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
MEP36008A (en) 1999-08-31 2011-02-10 Bayer Schering Pharma Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
ME00292B (me) * 2000-01-18 2011-05-10 Schering Ag Drospirenon za terapiju zamjene hormona
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
JP2004521951A (ja) * 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
EP1485105A1 (en) * 2002-03-18 2004-12-15 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
MXPA04009033A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de receptor de aldosterona y acido nicotinico o un derivado de acido nicotinico.
ITMI20040367A1 (it) * 2004-03-01 2004-06-01 Ind Chimica Srl Processo per la preparazione di drospirenone
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
HUP0402466A2 (en) * 2004-11-30 2006-07-28 Richter Gedeon Vegyeszet Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
HUP0402465A2 (en) * 2004-11-30 2006-07-28 Richter Gedeon Vegyeszet Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
WO2008137050A2 (en) * 2007-05-01 2008-11-13 Sicor Inc. A process for preparing drospirenone and intermediate thereof
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
HUP0700826A3 (en) 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
EP2265629B1 (en) * 2008-03-05 2015-06-24 Evestra, Inc. Bismethylene-17 carbolactones and related uses
WO2010068500A2 (en) * 2008-11-25 2010-06-17 Evestra, Inc. PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a -YL) PROPIONIC ACID g-LACTONES
CA2752805A1 (en) 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
WO2010094624A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
ES2432063T3 (es) 2009-06-16 2013-11-29 Crystal Pharma, S.A.U. Procedimiento para la obtención de 17-espirolactonas en esteroides
CA2796307A1 (en) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102887934B (zh) * 2012-09-20 2015-05-27 杭州福斯特药业有限公司 一种屈螺酮的制备方法
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
EP3108889A1 (en) 2015-06-23 2016-12-28 Philippe Perrin Drospirenone-based contraceptive for a female patient affected with excess weight
SI3313408T1 (sl) 2015-06-23 2024-04-30 Laboratorios Leon Farma Sa Kontraceptiv na osnovi drospirenona za pacientko s prekomerno težo
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
AR128632A1 (es) 2022-03-01 2024-05-29 Chemo Res S L Anticonceptivo oral masticable de drospirenona

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
NL166267C (nl) * 1968-03-22 1981-07-15 Merck & Co Inc Werkwijze ter bereiding van farmaceutische preparaten, de onder toepassing daarvan verkregen gevormde voort- brengselen, alsmede werkwijze ter bereiding van 6,7-methyleen-20-spirox-4-en-3-onderivaten met aldoste- ron remmende werking.
DE2237143A1 (de) * 1972-07-28 1974-02-14 Hoechst Ag Verfahren zur herstellung von beta(3-keto-7alpha-acetylthio-17beta-hydroxy4-androsten-17alpha-yl)-propionsaeuregamma-lacton und dessen 1-dehydro-derivat
CH601352A5 (es) * 1973-09-26 1978-07-14 Hoffmann La Roche

Also Published As

Publication number Publication date
FR2370755B1 (es) 1980-06-06
SU695560A3 (ru) 1979-10-30
JPS5363373A (en) 1978-06-06
IT1092262B (it) 1985-07-06
SU743582A3 (ru) 1980-06-25
LU78514A1 (es) 1978-03-20
CH632774A5 (de) 1982-10-29
SE7712891L (sv) 1978-05-17
GR65227B (en) 1980-07-30
AU512611B2 (en) 1980-10-16
IL53353A0 (en) 1978-01-31
ATA815577A (de) 1979-10-15
DK141967B (da) 1980-07-28
DD132968A5 (de) 1978-11-22
AU3050977A (en) 1979-05-17
CA1092094A (en) 1980-12-23
IE46076B1 (en) 1983-02-09
US4129564A (en) 1978-12-12
DD132968B3 (de) 1991-03-28
GB1550568A (en) 1979-08-15
BE860877A (fr) 1978-05-16
IE46076L (en) 1978-05-16
DE2652761C2 (de) 1985-11-21
CH631463A5 (de) 1982-08-13
DK508077A (da) 1978-05-17
JPS61218595A (ja) 1986-09-29
SE436425B (sv) 1984-12-10
AT356827B (de) 1980-05-27
DE2652761A1 (de) 1978-05-18
IL53353A (en) 1982-04-30
JPS6156240B2 (es) 1986-12-01
HU174983B (hu) 1980-04-28
DK141967C (da) 1980-12-08
JPH0242840B2 (es) 1990-09-26
CS194823B2 (en) 1979-12-31
FR2370755A1 (fr) 1978-06-09
NL7711946A (nl) 1978-05-18

Similar Documents

Publication Publication Date Title
ES464193A1 (es) Procedimiento para la preparacion de espirolactonas.
ES461762A1 (es) Un procedimiento para preparar una composicion tintorea parafibras queratinicas.
PL218318A1 (es)
FI761352A (es)
ES8300785A1 (es) Procedimiento de preparar esteroides e intermedios de este- roides antiinflamatorios
ES405983A1 (es) Procedimiento para la preparacion de derivados de fenileti-lamina fluoralcohilados.
ES474666A1 (es) Procedimiento para la preparacion de alcohil-sulfato-betai- nas que contienen fluor
ES470746A1 (es) Un procedimiento para preparar derivados de dihidropirano 6-sustituido
ES8200108A1 (es) Un procedimiento para la preparacion de derivados de tioxan tina.
ES473075A1 (es) Procedimiento para la preparacion de colorantes 5-triacini- cos
ES481551A1 (es) Procedimiento de preparacion de nuevos compuestos bis (ari- loxicarboxilicos).
ES464728A1 (es) Procedimiento para producir derivados del acido propionico
GR78685B (es)
ES455158A1 (es) Procedimiento para la preparacion de derivados de di-n-oxidode quinoxalina.
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
ES471267A1 (es) Procedimiento para la preparacion de alquilo inferior 2-tri-(inferior) alquilsililacetileno-n-carbetoxiglicinatos y ami-no acidos derivados de ellos
GB1098103A (en) Improvements in or relating to steroid compounds
DE3560110D1 (en) Derivatives of 2-alkoxyaminosulfonylbenzenesulfonylurea
ES436781A1 (es) Procedimiento para la preparacion de derivados de la diteo- filina.
ES445263A1 (es) Un procedimiento para preparar un nuevo derivado de dimer- captoetileter.
ES467237A1 (es) Procedimiento para la preparacion de derivados de ciclopro- pano.
ES8506580A1 (es) Un procedimiento para la produccion de compuestos poliprenilicos
EP0139907A3 (en) Estrane derivatives
ES449718A1 (es) Procedimiento para la obtencion de esteres de acidos o-etil-o-piridaciniltiono-bencenosfosfonicos de efecto insecticida y acaricida.
ES459654A1 (es) Procedimiento para la obtencion de alquinoles.